Company profile
Whitehawk Therapeutics, Inc.
NASDAQ:WHWKBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07470853 | phase1 | recruiting | 2026-03-15 | 2028-02-01 | Whitehawk Therapeutics, Inc. | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. |
| NCT07444814 | phase1 | recruiting | 2025-12-19 | 2028-10-01 | Whitehawk Therapeutics, Inc. | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors |
FDA applications (0)
No records yet.